Development of potent JAK2 inhibitors for MPN treatment needs to satisfy several criteria. First, they must be specific to JAKs over other kinases to avoid any off-target toxicity. Drug exploitation ...

The MarketWatch News Department was not involved in the creation of this content. DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biotechnology company developing next-generation ...

Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type JAK2 ...

Several lines of evidence point to the key role of constitutively active Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling in the pathogenesis of BCR-ABL-negative ...

Please provide your email address to receive an email when new articles are posted on . Riedlinger and colleagues assessed clinical sequencing data on 2,030 solid tumors examined at Rutgers University ...

ZRSR2 mutations are linked to JAK2 V617R-driven MPNs but are insufficient alone for disease progression. CRISPR-Cas9 studies showed ZRSR2 loss causes intron retention and transcriptional changes ...

Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models. Interpreting survival outcomes for ...

Brian C. Betts, David Bastian, Supinya Iamsawat, Hung Nguyen, Jessica L. Heinrichs, Yongxia Wu, Anusara Daenthanasanmak, Anandharaman Veerapathran, Alison O’Mahony ...

QIAGEN announced that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all ...

Improved outcome for acute lymphoblastic leukemia (ALL) in children and adolescents: Results of the MCP841—A two decades report from a developing country (India) No significant financial relationships ...

Picomolar potency and > 500-fold selectivity for JAK2 V617F JH2 versus WT JAK2 JH2 in cellular assays. 100× selective inhibition of pSTAT5 phosphorylation and proliferation in BaF3 JAK2 V617F and ...